The proposed transaction would create a Nasdaq-listed company focused on NET-targeting therapies, combining four clinical programs while transferring majority ownership to Santersus shareholders.
Key Investor Takeaways
- Xenetic Biosciences (NASDAQ:XBIO) has signed a definitive share exchange agreement to acquire privately held Santersus AG in an all-stock transaction.
- Existing Xenetic shareholders are expected to own approximately 15% of the combined company, while Santersus shareholders would hold 85%, subject to adjustments.
- The merger would combine four NET-targeting therapeutic programs, including two with FDA Breakthrough Device Designation.
- The combined company is expected to operate as Santersus Bio, Inc. under the proposed Nasdaq ticker SNTS.
- Completion is targeted for the fourth quarter of 2026, subject to shareholder approval, Nasdaq listing requirements and other closing conditions.
Why XBIO Stock Is in Focus
Xenetic Biosciences (NASDAQ:XBIO) announced on September 16 that it has entered into a definitive agreement to acquire all outstanding shares of Santersus AG through the issuance of new Xenetic common stock.
The transaction follows Xenetic’s strategic review and would substantially change the company’s ownership, management and clinical development portfolio.
Under the proposed terms, Santersus shareholders would receive approximately 85% of the combined company’s equity, calculated on a fully diluted and as-converted basis. Xenetic shareholders would retain approximately 15%.
The final ownership percentages remain subject to adjustments, including Xenetic’s net cash balance at closing.
Following completion, Santersus would become a wholly owned subsidiary of Xenetic, which would be renamed Santersus Bio, Inc.
Santersus Chief Executive Officer James Ladtkow would lead the combined organization, supported by the existing Santersus management team.
The new board would comprise eight directors, including six Santersus nominees and two Xenetic nominees.
The companies also announced 180-day post-closing lock-up agreements covering specified shareholders, directors, officers and other parties, subject to limited exceptions.
Combined Pipeline Brings Four NET-Targeting Programs Together
The proposed merger combines two technologies designed to target neutrophil extracellular traps, or NETs, which are implicated in several disease processes.
Santersus contributes NucleoCapture, a blood purification platform designed to physically remove NETs from circulation. Xenetic contributes its DNase technology, which is designed to enzymatically degrade NETs in tissue.
The combined pipeline would include four principal programs:
- Sepsis: NucleoCapture is being evaluated in a pivotal clinical study alongside standard care and has received FDA Breakthrough Device Designation.
- Systemic lupus erythematosus: A second NucleoCapture program is advancing toward pivotal testing and has also received Breakthrough Device Designation.
- Liver transplantation: NucleoCapture is being developed to improve donor liver quality during machine perfusion and is ready to enter pivotal studies following research involving donated human livers.
- B-cell lymphoma: Xenetic’s DNase technology is being evaluated in a Phase 1b investigator-initiated study in Israel alongside anti-CD19 CAR-T therapy.
The two platforms target NETs through different mechanisms, potentially broadening the combined company’s therapeutic development opportunities.
However, FDA Breakthrough Device Designation does not constitute marketing approval, and the programs remain subject to clinical and regulatory development.
Why This Matters for Investors
The proposed all-stock merger introduces a substantial change to Xenetic’s investment profile.
Existing shareholders would retain a minority position in a company primarily owned and managed by Santersus stakeholders, making the proposed ownership structure a central consideration.
The transaction could also shift the company’s development priorities by adding pivotal-stage medical device programs in sepsis and autoimmune disease to Xenetic’s existing oncology-focused technology.
This would broaden the clinical pipeline while introducing additional development, regulatory and execution requirements.
For investors assessing the transaction, the combination of two NET-targeting technologies provides a common scientific focus across multiple indications. Nevertheless, clinical progress in one program would not establish the effectiveness of the others.
The announcement does not disclose a transaction valuation, combined cash position or projected operating expenses.
These omissions limit the ability to assess the financial implications of the merger, including the combined company’s funding requirements and potential need for additional capital.
The proposed ownership allocation also means that any adjustments linked to Xenetic’s closing net cash balance could affect the final equity interests of existing shareholders.
What to Watch Next
The transaction is expected to close in the fourth quarter of 2026, with several conditions still outstanding.
Xenetic shareholders must approve the agreement, the newly issued shares must receive Nasdaq listing approval, and a resale registration statement on Form S-1 must become effective.
Investors can also monitor the forthcoming SEC filings for additional transaction details and information about the combined company’s financial position.
Beyond completion, the principal clinical milestones will include progress in the pivotal sepsis study, initiation of the planned lupus trial and further development of the liver transplantation and lymphoma programs.
Until the required approvals are secured, Xenetic and Santersus remain separate companies, and the proposed merger is not guaranteed to close.